The survival analysis of rifampicin/multidrug-resistant tuberculosis patients based on the levels of inflammatory biomarkers: a retrospective cohort study
PurposeThe development of tuberculosis and inflammatory status are closely related. The aim of this study was to investigate the prognostic value of inflammatory biomarkers in patients with rifampicin/multidrug-resistant tuberculosis (RR/MDR-TB).Patients and methodsThis study recruited 504 patients...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-05-01
|
| Series: | Frontiers in Cellular and Infection Microbiology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcimb.2023.1118424/full |
| _version_ | 1827956425202073600 |
|---|---|
| author | Qi Yu Hong Luo Shengling Hu Dan Sun Qi Nie Jisong Yan |
| author_facet | Qi Yu Hong Luo Shengling Hu Dan Sun Qi Nie Jisong Yan |
| author_sort | Qi Yu |
| collection | DOAJ |
| description | PurposeThe development of tuberculosis and inflammatory status are closely related. The aim of this study was to investigate the prognostic value of inflammatory biomarkers in patients with rifampicin/multidrug-resistant tuberculosis (RR/MDR-TB).Patients and methodsThis study recruited 504 patients with RR/MDR-TB from Wuhan Jinyintan Hospital. A total of 348 RR/MDR patients from January 2017 to December 2019 were defined as training set, the rest of patients as validation set. The patients were divided into three-risk degrees according to the levels of inflammatory biomarkers (median, 85th percentile). Kaplan-Meier curve and log-rank test were used to assess survival differences among the groups. Cox proportion risk regression was used to identify risk factors for RR/MDR-TB mortality.ResultsIn training set, cox proportion risk regression analysis showed that high age (≥60 years) [OR (95%CI):1.053(1.03188-1.077)], smoking [OR (95%CI):2.206(1.191-4.085)], and bronchiectasia [OR (95%CI):2.867(1.548-5.311)] were prognostic factors for RR/MDR-TB patients. In addition, lower survival rates were observed in high CAR group [OR (95%CI):1.464(1.275-1.681)], high CPR group[OR (95%CI):1.268(1.101-1.459)], high CLR group[OR (95%CI):1.004(1.002-1.005)], high NLR group[OR (95%CI):1.103(1.069-1.139)], high PLR group[OR (95%CI):1.003(1.002-1.004)], and high MLR group[OR (95%CI):3.471(2.188-5.508)].Furthermore, AUCs of age, smoking, bronchiectasia, CAR, CPR, CLR, NLR, PLR, and MLR for predicting mortality in RR/MDR-TB patients were 0.697(95%CI:0.618-0.775), 0.603(95%CI:0.512-0.695), 0.629(95%CI:0.538-0.721), 0.748(95%CI:0.675-0.821, P<0.05), 0.754(95%CI:0.683-0.824, P<0.05), 0.759(95%CI:0.689-0.828, P<0.05), 0.789(95%CI:0.731-0.846, P<0.05), 0.740(95%CI:0.669-0.812, P<0.05), and 0.752(95%CI:0.685-0.819, P<0.05), respectively. Importantly, the AUC of predicting mortality of combination of six inflammatory biomarkers [0.823 (95%CI:0.769-0.876)] is higher than any single inflammatory biomarkers. Additionally, the similar results are also obtained in the validation set.ConclusionInflammatory biomarkers could predict the survival status of RR/MDR-TB patients. Therefore, more attention should be paid to the level of inflammatory biomarkers in clinical practice. |
| first_indexed | 2024-04-09T15:04:12Z |
| format | Article |
| id | doaj.art-9508fe8ef6ca46019eff17d526b9221a |
| institution | Directory Open Access Journal |
| issn | 2235-2988 |
| language | English |
| last_indexed | 2024-04-09T15:04:12Z |
| publishDate | 2023-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cellular and Infection Microbiology |
| spelling | doaj.art-9508fe8ef6ca46019eff17d526b9221a2023-05-01T04:25:47ZengFrontiers Media S.A.Frontiers in Cellular and Infection Microbiology2235-29882023-05-011310.3389/fcimb.2023.11184241118424The survival analysis of rifampicin/multidrug-resistant tuberculosis patients based on the levels of inflammatory biomarkers: a retrospective cohort studyQi Yu0Hong Luo1Shengling Hu2Dan Sun3Qi Nie4Jisong Yan5Department of Infectious Diseases, Wuhan Jinyintan Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, ChinaDepartment of Respiratory and Critical Care Medicine, Wuhan Jinyintan Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, ChinaDepartment of Infectious Diseases, Wuhan Jinyintan Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, ChinaDepartment of Interventional Therapy, Wuhan Pulmonary Hospital, Wuhan, Hubei, ChinaDepartment of MDR/RR-TB, Wuhan Jinyintan Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, ChinaDepartment of Respiratory and Critical Care Medicine, Wuhan Jinyintan Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, ChinaPurposeThe development of tuberculosis and inflammatory status are closely related. The aim of this study was to investigate the prognostic value of inflammatory biomarkers in patients with rifampicin/multidrug-resistant tuberculosis (RR/MDR-TB).Patients and methodsThis study recruited 504 patients with RR/MDR-TB from Wuhan Jinyintan Hospital. A total of 348 RR/MDR patients from January 2017 to December 2019 were defined as training set, the rest of patients as validation set. The patients were divided into three-risk degrees according to the levels of inflammatory biomarkers (median, 85th percentile). Kaplan-Meier curve and log-rank test were used to assess survival differences among the groups. Cox proportion risk regression was used to identify risk factors for RR/MDR-TB mortality.ResultsIn training set, cox proportion risk regression analysis showed that high age (≥60 years) [OR (95%CI):1.053(1.03188-1.077)], smoking [OR (95%CI):2.206(1.191-4.085)], and bronchiectasia [OR (95%CI):2.867(1.548-5.311)] were prognostic factors for RR/MDR-TB patients. In addition, lower survival rates were observed in high CAR group [OR (95%CI):1.464(1.275-1.681)], high CPR group[OR (95%CI):1.268(1.101-1.459)], high CLR group[OR (95%CI):1.004(1.002-1.005)], high NLR group[OR (95%CI):1.103(1.069-1.139)], high PLR group[OR (95%CI):1.003(1.002-1.004)], and high MLR group[OR (95%CI):3.471(2.188-5.508)].Furthermore, AUCs of age, smoking, bronchiectasia, CAR, CPR, CLR, NLR, PLR, and MLR for predicting mortality in RR/MDR-TB patients were 0.697(95%CI:0.618-0.775), 0.603(95%CI:0.512-0.695), 0.629(95%CI:0.538-0.721), 0.748(95%CI:0.675-0.821, P<0.05), 0.754(95%CI:0.683-0.824, P<0.05), 0.759(95%CI:0.689-0.828, P<0.05), 0.789(95%CI:0.731-0.846, P<0.05), 0.740(95%CI:0.669-0.812, P<0.05), and 0.752(95%CI:0.685-0.819, P<0.05), respectively. Importantly, the AUC of predicting mortality of combination of six inflammatory biomarkers [0.823 (95%CI:0.769-0.876)] is higher than any single inflammatory biomarkers. Additionally, the similar results are also obtained in the validation set.ConclusionInflammatory biomarkers could predict the survival status of RR/MDR-TB patients. Therefore, more attention should be paid to the level of inflammatory biomarkers in clinical practice.https://www.frontiersin.org/articles/10.3389/fcimb.2023.1118424/fullrifampicin/multidrug-resistant tuberculosisprognosisinflammatory markersclincial featuresinflammation |
| spellingShingle | Qi Yu Hong Luo Shengling Hu Dan Sun Qi Nie Jisong Yan The survival analysis of rifampicin/multidrug-resistant tuberculosis patients based on the levels of inflammatory biomarkers: a retrospective cohort study Frontiers in Cellular and Infection Microbiology rifampicin/multidrug-resistant tuberculosis prognosis inflammatory markers clincial features inflammation |
| title | The survival analysis of rifampicin/multidrug-resistant tuberculosis patients based on the levels of inflammatory biomarkers: a retrospective cohort study |
| title_full | The survival analysis of rifampicin/multidrug-resistant tuberculosis patients based on the levels of inflammatory biomarkers: a retrospective cohort study |
| title_fullStr | The survival analysis of rifampicin/multidrug-resistant tuberculosis patients based on the levels of inflammatory biomarkers: a retrospective cohort study |
| title_full_unstemmed | The survival analysis of rifampicin/multidrug-resistant tuberculosis patients based on the levels of inflammatory biomarkers: a retrospective cohort study |
| title_short | The survival analysis of rifampicin/multidrug-resistant tuberculosis patients based on the levels of inflammatory biomarkers: a retrospective cohort study |
| title_sort | survival analysis of rifampicin multidrug resistant tuberculosis patients based on the levels of inflammatory biomarkers a retrospective cohort study |
| topic | rifampicin/multidrug-resistant tuberculosis prognosis inflammatory markers clincial features inflammation |
| url | https://www.frontiersin.org/articles/10.3389/fcimb.2023.1118424/full |
| work_keys_str_mv | AT qiyu thesurvivalanalysisofrifampicinmultidrugresistanttuberculosispatientsbasedonthelevelsofinflammatorybiomarkersaretrospectivecohortstudy AT hongluo thesurvivalanalysisofrifampicinmultidrugresistanttuberculosispatientsbasedonthelevelsofinflammatorybiomarkersaretrospectivecohortstudy AT shenglinghu thesurvivalanalysisofrifampicinmultidrugresistanttuberculosispatientsbasedonthelevelsofinflammatorybiomarkersaretrospectivecohortstudy AT dansun thesurvivalanalysisofrifampicinmultidrugresistanttuberculosispatientsbasedonthelevelsofinflammatorybiomarkersaretrospectivecohortstudy AT qinie thesurvivalanalysisofrifampicinmultidrugresistanttuberculosispatientsbasedonthelevelsofinflammatorybiomarkersaretrospectivecohortstudy AT jisongyan thesurvivalanalysisofrifampicinmultidrugresistanttuberculosispatientsbasedonthelevelsofinflammatorybiomarkersaretrospectivecohortstudy AT qiyu survivalanalysisofrifampicinmultidrugresistanttuberculosispatientsbasedonthelevelsofinflammatorybiomarkersaretrospectivecohortstudy AT hongluo survivalanalysisofrifampicinmultidrugresistanttuberculosispatientsbasedonthelevelsofinflammatorybiomarkersaretrospectivecohortstudy AT shenglinghu survivalanalysisofrifampicinmultidrugresistanttuberculosispatientsbasedonthelevelsofinflammatorybiomarkersaretrospectivecohortstudy AT dansun survivalanalysisofrifampicinmultidrugresistanttuberculosispatientsbasedonthelevelsofinflammatorybiomarkersaretrospectivecohortstudy AT qinie survivalanalysisofrifampicinmultidrugresistanttuberculosispatientsbasedonthelevelsofinflammatorybiomarkersaretrospectivecohortstudy AT jisongyan survivalanalysisofrifampicinmultidrugresistanttuberculosispatientsbasedonthelevelsofinflammatorybiomarkersaretrospectivecohortstudy |